CNS Disorders  >>  crenezumab (RG7412)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenezumab (RG7412) / AC Immune
NCT00736775: A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

Completed
1
56
US
anti-Abeta, placebo
Genentech, Inc.
Alzheimer's Disease
05/10
 
NCT02353598: A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

Checkmark Dose escalation study in AD at CTAD 2016
Dec 2016 - Dec 2016: Dose escalation study in AD at CTAD 2016
Completed
1
77
US
Crenezumab dose level 1, Crenezumab dose level 2, Crenezumb dose level 3, Placebo
Genentech, Inc.
Alzheimer Disease
11/16
03/19

Download Options